Soterix announces expanded clinical trials for Alzheimer’s disease

Medical tech co validates non-invasive non-drug therapies not simply to both treat diagnosed Alzheimer's disease and Mild Cognitive Impairment but also stabilize, and even reverse, age-related cognitive decline


SoterixSoterix Medical Inc has announced expanded clinical trials of its proprietary neuromodulation technologies for Alzheimer’s disease and Mild Cognitive Impairment.

The company is a leaing player in non-invasive stimulation and synergistic brain imaging technologies.

According to Jose Rodriguez, Soterix Medical’s VP Regulatory Affairs, “Soterix Medical is enthusiastic to support our medical partners around the world in conducting the most rigorous clinical trials for non-invasive neuromodulation in Alzheimer’s disease and Mild Cognitive Impairment.”

He added that they feel the funding support for these trials from government agencies such as the NIH and VA further supports their rigor and importance. And with the inclusion of state-of-the-art biomarkers testing, these trials can not only demonstrate efficacy, but prove target engagement.

Dr Abhishek Datta, CTO of Soterix Medical, stated, “The application of unique Soterix Medical technology to develop treatments for age-related cognitive decline demonstrates the versatile capabilities of our platforms.”

These include Soterix Medical SNAPpad and HD electrodes, by far the most successful and trusted tDCS electrodes, he said and added that their capabilities to support the most controlled double-bind trials, and to provide unique delivery platforms both at medical centers and at-home.

Adults over age 65 represent the fastest growing population in the US. Decline in cognitive abilities is a hallmark of advanced age and is associated with loss of independence and dementia risk. Over 50 million adults worldwide are diagnosed with Alzheimer’s disease or other dementia, which puts an enormous burden on individuals, their families and caretakers, and the healthcare system.

Soterix Medical technologies are at the forefront of validation of non-invasive non-drug therapies not simply to both treat diagnosed Alzheimer’s disease and Mild Cognitive Impairment but also stabilize, and even reverse, age-related cognitive decline.

Support from NIH

With $6.2 million of support from the National Institutes of Health (NIH) National Institute of Aging (NIA), the Albert Einstein College of Medicine, Montefiore Health System, and the MJHS Health System will evaluate the effectiveness of tDCS to alleviate symptoms of Alzheimer’s disease and improve brain function.

Trending News

This new trial will leverage Soterix Medical’s unique at-home tDCS platform, the mini-CT stimulator and ElectraRx remote control software. The randomized, double-blind study will evaluate the effects of six months of at-home tDCS on improving cognitive performance and selected symptoms in 100 patients with mild-to-moderate Alzheimer’s disease.

(With inputs from The OnLook News Research Bureau)

If you like this article and if you feel it will be helpful for others to understand on the subject, please share it. You can also follow us on Twitter,  Facebook & Linkedin

Also read: NIH starts study of Covid infection and multisystem inflammatory syndrome

Trending News